RECURSION PHARMACEUTICALS-A
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.
Find out what a historical investment in RECURSION PHARMACEUTICALS-A would be worth today using our RXRX stock calculator.
$2.33B
-
0.00%
14.91M
$5.63
$5.24
$5.47
$12.36
$3.79
Ready to start your investing journey with Stake?
Open an accountRXRX FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in RXRX
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in RXRX
on Stake
Buy RXRX from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of RXRX from only US$10 with fractional shares
